---
layout: post
title: ' New Drug Approvals 2012 - Pt. XXII - Perampanel (FycompaTM)'
date: '2012-11-01T06:40:00.001Z'
author: Gerard JP van Westen
tags:
- Small Molecule Drugs
- Black Box Warning Drugs
- Allosterism
- 2012 New Drugs
modified_time: '2012-11-01T06:49:36.394Z'
thumbnail: http://1.bp.blogspot.com/-VQucKR1APbg/UJELuujxUJI/AAAAAAAAGWk/lJ3SdD6LjKs/s72-c/fycompa-logo.gif
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8621926850938090895
blogger_orig_url: http://chembl.blogspot.com/2012/11/new-drug-approvals-2012-pt-xxii.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-VQucKR1APbg/UJELuujxUJI/AAAAAAAAGWk/lJ3SdD6LjKs/s1600/fycompa-logo.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="127" src="http://1.bp.blogspot.com/-VQucKR1APbg/UJELuujxUJI/AAAAAAAAGWk/lJ3SdD6LjKs/s320/fycompa-logo.gif" width="320" /></a></div>
<div style="text-align: center;">
</div>
<div style="text-align: center;">
</div>
<br />
<center face="arial">
</center>
<center face="arial">
</center>
<center face="arial">
<img height="37" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,0,0,1" width="320" /></center>
<div style="text-align: center;">
<br />
<b>ATC Code</b>: <a href="http://www.whocc.no/atc_ddd_index/?code=N03AX22">N03AX22</a></div>
<div style="text-align: center;">
<b>Wikipedia</b>: <a href="http://en.wikipedia.org/wiki/Perampanel">Perampanel</a> </div>
<br />
On October 22nd 2012 the FDA approved Perampanel (research code: E2007, ER-155055-90, trade name Fycompa,               <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1214124">CHEMBL1214124</a>). Perampanel is an orally administered drug  to be used as an adjunctive therapy for the treatment of partial-onset  seizures with or without secondary generalized seizures in patients with <a href="http://en.wikipedia.org/wiki/Seizure"> epilepsy</a>. <br />
<br />
Epileptic seizures are defined as "abnormal excessive or <a href="http://www.blackwell-synergy.com/doi/full/10.1111/j.0013-9580.2005.66104.x">synchronous neuronal activity</a> in the brain". The net symptoms can be very diverse, from severe thrashing movements to a very mild brief loss of awareness. Approximately 4% of the population will have experienced a <a href="http://dx.doi.org/10.1007%2Fs11940-004-0016-5">unprovoked seizure </a>by the age of 80, with a 30-50% chance of repeat in this group. Seizures can last from a few seconds to a state of life threatening persistent seizure (known as <a href="http://en.wikipedia.org/wiki/Status_epilepticus">status epilepticus</a>). <br />
<br />
Approximately 25 % of the people suffering from a seizure or&nbsp; status epilepticus will be diagnosed to have <a href="http://www.ncbi.nlm.nih.gov/pubmed/19605972">epilepsy</a>. Treatment may reduce the chance of a second seizure by as much as <a href="http://www.ncbi.nlm.nih.gov/pubmed/18184">50%</a>. <br />
<br />
Perampanel acts by non-competitively inhibiting the ionotropic Î±-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) glutamate receptor. This receptor consists of a<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117497/"> heteromeric combination </a>of 2 out of 4 known subunits GluR-1 - GluR4 (respectively: <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2009">CHEMBL2009</a>, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL4016">CHEMBL4016</a>, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL3595">CHEMBL3595</a> and <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL3190">CHEMBL3190</a> or Uniprot <a href="http://www.uniprot.org/uniprot/P42261">42261</a>, <a href="http://www.uniprot.org/uniprot/P42262">42262</a>, <a href="http://www.uniprot.org/uniprot/P42263">42263</a> and <a href="http://www.uniprot.org/uniprot/P48058">48058</a>). Of these, the combinations GluR-1/GluR-2 and GluR-2/GluR-3 are the most frequent. The specific mechanism by which Perampanel exerts its antiepileptic effect in humans has not been fully elucidated.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-gqnS_97Pup0/UJD8jM8gmXI/AAAAAAAAGWU/MJyMw6pi9kM/s1600/Screen+Shot+2012-10-31+at+10.25.06.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="175" src="http://3.bp.blogspot.com/-gqnS_97Pup0/UJD8jM8gmXI/AAAAAAAAGWU/MJyMw6pi9kM/s200/Screen+Shot+2012-10-31+at+10.25.06.png" width="200" /></a></div>
<br />
<br />
Fycompa is a small molecule drug with a molecular mass of 349.4  g/mol, an AlogP of 3.57 , 3 rotatable bonds and does not violate the rule  of 5.&nbsp;<b>Canonical SMILES</b> :     O=C1N(C=C(C=C1c2ccccc2C#N)c3ccccn3)c4ccccc4<br />
<b>InChi</b>: InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H<br />
<br />
The recommended starting dose of Perampanel in the absence of other CYP3A4 enzyme-inducing antiepileptic drugs is 2 mg once daily taken orally at bedtime (and can be incremented to the recommended dose range of 8 mg to 12 mg once daily).&nbsp;The recommended starting dose of Perampanel in the presence of CYP3A4  enzyme-inducing antiepileptic drugs is 4 mg and patients should be monitored closely for response.<br />
<br />
Perampanel is extensively metabolized <i>via</i> initial oxidation and sequential glucuronidation. Oxidative metabolism is mediated by CYP3A4 and/or CYP3A5 based on results of in vitro studies using recombinant human CYPs and human liver microsomes. Other CYP enzymes may also be involved.<br />
<br />
The license holder is <a href="http://us.eisai.com/">Eisai Inc.</a> and the full prescribing information can be found <a href="http://us.eisai.com/package_inserts/FycompaPI.pdf">here</a>.</div>